The genesis of high-throughput structure-based drug discovery using protein crystallography

Current Opinion in Chemical Biology

Volumn 6, Issue 5, 2002, Pages 704-710

  Kuhn, Peter ^a,d   Wilson, Keith ^b   Patch, Marianne G ^c   Stevens, Raymond C ^c,d  

^a SLAC NATIONAL ACCELERATOR LABORATORY   (United States)

^b Takeda San Diego Inc   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Joint Center for Structural Genomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DRUG; LIGAND; NELFINAVIR; OSELTAMIVIR; PROTEINASE; PROTEINASE INHIBITOR; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMAGE ANALYSIS; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RELIABILITY; REVIEW; ROBOTICS; SCREENING TEST; SYNCHROTRON; TECHNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036804362     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(02)00361-7     Document Type: Review

References (73)

1. Kaldor S.W., Kalish V.J., Davies J.F. I.I., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 40:1997;3979-3985.
2. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc. 117:1995;1181-1182.
3. von Itzstein M., Wu W.-Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Phan T.V., Smythe M.L., White H.F., Oliver S.W., Colman P.M., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
4. Kim C.U., Lew W., Williams M.A., Liu H.T., Zhang L.J., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 119:1997;681-690.
5. Gilbert M., Albala J.S. Accelerating code to function: sizing up the protein production line. Curr Opin Chem Biol. 6:2002;102-105.
6. Lesley S.A. High-throughput proteomics: protein expression and purification in the postgenomic world. Protein Expr Purif. 22:2001;159-164. The instrumentation and data analysis described in this paper exemplifies the critical aspects of automated sample preparation that are required for HT structural biology and structural genomics efforts.
7. Stevens R.C. Design of high-throughput methods of protein production for structural biology. Struct Fold Des. 8:2000;R177-R185.
8. Waldo G.S., Standish B.M., Berendzen J., Terwilliger T.C. Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol. 17:1999;691-695.
9. Guss J.M., Merritt E.A., Phizackerley R.P., Hedman B., Murata M., Hodgson K.O., Freeman H.C. Phase determination by multiple-wavelength X-ray diffraction: crystal structure of a basic "blue" copper protein from cucumbers. Science. 241:1988;806-811.
10. Hendrickson W.A., Horton J.R., LeMaster D.M. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure. EMBO J. 9:1990;1665-1672.
11. Garman E. Cool data: quantity AND quality. Acta Crystallogr D. 55:1999;1641-1653.
12. Abola E., Kuhn P., Earnest T., Stevens R.C. Automation of X-ray crystallography. Nat Struct Biol. 7:2000;973-977.
13. Muchmore S.W., Olson J., Jones R., Pan J., Blum M., Greer J., Merrick S.M., Magdalinos P., Nienaber V.L. Automated crystal mounting and data collection for protein crystallography. Struct Fold Des. 8:2000;R243-R246.
14. Adams P.D., Grosse-Kunstleve R.W. Recent developments in software for the automation of crystallographic macromolecular structure determination. Curr Opin Struct Biol. 10:2000;564-568. Automation and software integration of the entire structure determination and refinement process is a critical enabling technology, for which new approaches are discussed in this paper.
15. Perrakis A., Morris R., Lamzin V.S. Automated protein model building combined with iterative structure refinement. Nat Struct Biol. 6:1999;458-463. Perhaps one the most important breakthroughs in crystallographic structure determination has been the use of ARP/wARP in the automatic tracing of high-resolution phased diffraction data and rebuilding of partial models.
16. Stevens R.C. High-throughput protein crystallization. Curr Opin Struct Biol. 10:2000;558-563.
17. Goodwill KE, Tennant MG, Stevens RC: High-throughput X-ray crystallography for structure-based drug design. Drug Discovery Today 2001, 6 (Genomics Suppl):S113-118.
18. Santarsiero B.D., Yegian D.T., Lee C.C., Spraggon G., Gu J., Scheibe D., Uber D.C., Cornell E.W., Nordmeyer R.A., Kolbe W.F., et al. An approach to rapid protein crystallization using nanodroplets. J Appl Crystallogr. 35:2002;278-281. This paper describes the technology of using nanoliter volumes for protein crystallization trials.
19. Luft J.R., Wolfley J., Jurisica I., Glasgow J., Fortier S., DeTitta G.T. Macromolecular crystallization in a high throughput laboratory-the search phase. J Cryst Growth. 232:2001;591-595.
20. Mueller U., Nyarsik L., Horn M., Rauth H., Przewieslik T., Saenger W., Lehrach H., Eickhoff H. Development of a technology for automation and miniaturization of protein crystallization. J Biotechnol. 85:2001;7-14.
21. Jurisica I., Rogers P., Glasgow J.I., Fortier S., Luft J.R., Wolfley J.R., Bianca M.A., Weeks D.R., DeTitta G.T. Intelligent decision support for protein crystal growth. IBM Systems J. 40:2001;394-409.
22. Long A. Drug discovery tutorial: high-throughput protein crystallization. Gen Eng News. 21:(34):2001;62.
23. Heinemann U. The Berlin "protein structure factory" initiative: a technology-oriented approach to structural genomics. Ernst Schering Res Found Workshop. 34:2001;101-121.
24. Klebe G. Recent developments in structure-based drug design. J Mol Med. 78:2000;269-281.
25. Abagyan R., Totrov M. High-throughput docking for lead generation. Curr Opin Chem Biol. 5:2001;375-382.
26. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov. 1:2002;45-54.
27. Charifson P.S., Corkery J.J., Murcko M.A., Walters W.P. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem. 42:1999;5100-5109. Individual docking algorithms appear to have biases towards certain biological target families and they all suffer from not being able to prioritize consistently. Using consensus scoring (multiple docking algorithms used at once), common hits are elevated above the others.
28. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 274:1996;1531-1534.
29. Nienaber V.L., Richardson P.L., Klighofer V., Bouska J.J., Giranda V.L., Greer J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol. 18:2000;1105-1108. Althoughcomputational screening has made significant advances, experimental screens are still more robust. This paper describes a novel method to experimentally screen compound libraries using crystallographic methods.
30. Wlodawer A., Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 27:1998;249-284.
31. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.C., Stutz S., Cumin F., Fuhrer W., Wood J.M., Grutter M.G. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 7:2000;493-504.
32. Maignan S., Mikol V. The use of 3D structural data in the design of specific factor Xa inhibitors. Curr Top Med Chem. 1:2001;161-174.
33. Liebeschuetz J.W., Jones S.D., Morgan P.J., Murray C.W., Rimmer A.D., Roscoe J.M., Waszkowycz B., Welsh P.M., Wylie W.A., Young S.C., et al. PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J Med Chem. 45:2002;1221-1232.
34. Chirgadze N.Y., Sall D.J., Briggs S.L., Clawson D.K., Zhang M., Smith G.F., Schevitz R.W. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors. Protein Sci. 9:2000;29-36.
35. Young W.B., Kolesnikov A., Rai R., Sprengeler P.A., Leahy E.M., Shrader W.D., Sangalang J., Burgess-Henry J., Spencer J., Elrod K., Cregar L. Optimization of a screening lead for factor VIIa/TF. Bioorg Med Chem Lett. 11:2001;2253-2256.
36. Hajduk P.J., Boyd S., Nettesheim D., Nienaber V., Severin J., Smith R., Davidson D., Rockway T., Fesik S.W. Identification of novel inhibitors of urokinase via NMR-based screening. J Med Chem. 43:2000;3862-3866.
37. Verner E., Katz B.A., Spencer J.R., Allen D., Hataye J., Hruzewicz W., Hui H.C., Kolesnikov A., Li Y., Luong C., et al. Development of serine protease inhibitors displaying a multicentered short (2.3 Å) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. J Med Chem. 44:2001;2753-2771.
38. Reich S.H., Johnson T., Wallace M.B., Kephart S.E., Fuhrman S.A., Worland S.T., Matthews D.A., Hendrickson T.F., Chan F., Meador J. III, et al. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation. J Med Chem. 43:2000;1670-1683.
39. Greenspan P.D., Clark K.L., Tommasi R.A., Cowen S.D., McQuire L.W., Farley D.L., van Duzer J.H., Goldberg R.L., Zhou H., Du Z., et al. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J Med Chem. 44:2001;4524-4534.
40. Katunuma N., Murata E., Kakegawa H., Matsui A., Tsuzuki H., Tsuge H., Turk D., Turk V., Fukushima M., Tada Y., Asao T. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett. 458:1999;6-10.
41. Furet P., Imbach P., Furst P., Lang M., Noorani M., Zimmermann J., Garcia-Echeverria C. Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. Bioorg Med Chem Lett. 11:2001;1321-1324.
42. Ghosh A.K., Bilcer G., Harwood C., Kawahama R., Shin D., Hussain K.A., Hong L., Loy J.A., Nguyen C., Koelsch G., et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem. 44:2001;2865-2868.
43. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
44. Furet P., Zimmermann J., Capraro H.G., Meyer T., Imbach P. Structure-based design of potent CDK1 inhibitors derived from olomoucine. J Comput Aided Mol Des. 14:2000;403-409.
45. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
46. Honma T., Hayashi K., Aoyama T., Hashimoto N., Machida T., Fukasawa K., Iwama T., Ikeura C., Ikuta M., Suzuki-Takahashi I., et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 44:2001;4615-4627.
47. Ghosh S., Liu X.-P., Zheng Y., Uckun F.M. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets. 1:2001;129-140.
48. Zhu X., Kim J.L., Newcomb J.R., Rose P.E., Stover D.R., Toledo L.M., Zhao H., Morgenstern K.A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure. 7:1999;651-661.
49. Shakespeare W., Yang M., Bohacek R., Cerasoli F., Stebbins K., Sundaramoorthi R., Azimioara M., Vu C., Pradeepan S., Metcalf C. III, et al. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA. 97:2000;9373-9378.
50. Fretz H., Furet P., Garcia-Echeverria C., Schoepfer J., Rahuel J. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr Pharm Des. 6:2000;1777-1796.
51. Iwata Y., Naito S., Itai A., Miyamoto S. Protein structure-based de novo design and synthesis of aldose reductase inhibitors. Drug Des Discov. 17:2001;349-359.
52. Mihelich E.D., Schevitz R.W. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. Biochim Biophys Acta. 1441:1999;223-228.
53. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 19:2000;6613-6626.
54. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., Croce C.M., Alnemri E.S., Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 97:2000;7124-7129.
55. Babu Y.S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliott A.J., Parker C.D., et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 43:2000;3482-3486.
56. Bressi J.C., Verlinde C.L., Aronov A.M., Shaw M.L., Shin S.S., Nguyen L.N., Suresh S., Buckner F.S., Van Voorhis W.C., Kuntz I.D., et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3- phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem. 44:2001;2080-2093.
57. Shahripour A.B., Plummer M.S., Lunney E.A., Albrecht H.P., Hays S.J., Kostlan C.R., Sawyer T.K., Walker N.P., Brady K.D., Allen H.J., et al. Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med Chem. 10:2002;31-40.
58. Webber S.E., Bleckman T.M., Attard J., Deal J.G., Kathardekar V., Welsh K.M., Webber S., Janson C.A., Matthews D.A., et al. Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolines. J Med Chem. 36:1993;733-746.
59. Iversen L.F., Andersen H.S., Moller K.B., Olsen O.H., Peters G.H., Branner S., Mortensen S.B., Hansen T.K., Lau J., Ge Y., et al. Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochem. 40:2001;14812-14820.
60. Doucet-Personeni C., Bentley P.D., Fletcher R.J., Kinkaid A., Kryger G., Pirard B., Taylor A., Taylor R., Taylor J., Viner R., et al. A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem. 44:2001;3203-3215.
61. Soper D.L., Milbank J.B., Mieling G.E., Dirr M.J., Kende A.S., Cooper R., Jee W.S., Yao W., Chen J.L., Bodman M., et al. Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. J Med Chem. 44:2001;4157-4169.
62. Schroder J., Henke A., Wenzel H., Brandstetter H., Stammler H.G., Stammler A., Pfeiffer W.D., Tschesche H. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J Med Chem. 44:2001;3231-3243.
63. Liao D., Basarab G.S., Gatenby A.A., Valent B., Jordan D.B. Structures of trihydroxynaphthalene reductase-fungicide complexes: implications for structure-based design and catalysis. Structure. 9:2001;19-27.
64. Debnath A.K. Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J Med Chem. 45:2002;41-53.
65. Palomer A., Pascual J., Cabre M., Borra's L., Gonzalez G., Aparici M., Carabaza A., Cabre F., Garcija M.L., Mauleon D. Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett. 12:2002;533-537.
66. Nicolotti O., Pellegrini-Calace M., Carrieri A., Altomare C., Centeno N.B., Sanz F., Carotti A. Neuronal nicotinic receptor agonists: a multi-approach development of the pharmacophore. J Comput Aided Mol Des. 15:2001;859-872.
67. Chen G.S., Chang C.S., Kan W.M., Chang C.L., Wang K.C., Chern J.W. Novel lead generation through hypothetical pharmacophore three-dimensional database searching: discovery of isoflavonoids as nonsteroidal inhibitors of rat 5 alpha-reductase. J Med Chem. 44:2001;3759-3763.
68. Gritsch S., Guccione S., Hoffmann R., Cambria A., Raciti G., Langer T. A 3D QSAR study of monoamino oxidase-B inhibitors using the chemical function based pharmacophore generation approach. J Enzyme Inhib. 16:2001;199-215.
69. Karki R.G., Kulkarni V.M. A feature based pharmacophore for Candida albicans myristoylCoA: protein N-myristoyltransferase inhibitors. Eur J Med Chem. 36:2001;147-163.
70. Aronov A.M., Munagala N.R., Ortiz De Montellano P.R., Kuntz I.D., Wang C.C. Rational design of selective submicromolar inhibitors of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase. Biochemistry. 39:2000;4684-4691.
71. Boehm H.J., Boehringer M., Bur D., Gmuender H., Huber W., Klaus W., Kostrewa D., Kuehne H., Luebbers T., Meunier-Keller N., Mueller F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem. 43:2000;2664-2674.
72. Grzybowski B.A., Ishchenko A.V., Kim C.Y., Topalov G., Chapman R., Christianson D.W., Whitesides G.M., Shakhnovich E.I. Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc Natl Acad Sci USA. 99:2002;1270-1273.
73. Guilloteau J.-P., Mathieu M., Giglione C., Blanc V., Dupuy A., Chevrier M., Gil P., Famechon A., Meinnel T., Mikol V. The Crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: A platform for the structure-based design of antibacterial agents. J Molec Biol. 320:2002;951-962.